Lebanese Interhospital Pneumococcal Surveillance Program

Sepsis Clinical Trial

— LIPSP  

Official title:

Lebanese Interhospital Pneumococcal Surveillance Program (LIPSP)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00901602
• Other study ID #: PNEUMOSurv1LIPSP
• Status: Recruiting
• Start date: October 2005
• Est. completion date: October 2030

Study information

• Verified date: February 2023
• Source: American University of Beirut Medical Center
• Contact: Ghassan S Dbaibo, M.D.
• Phone: +961-1-749235
• Email: gdbaibo[@]aub.edu.lb
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Streptococcus pneumoniae (pneumococcus) is a bacterium that causes severe infections in children and adults such as meningitis, pneumonia, and blood stream infection. There are many types of these bacteria defined by the type of sugar coat that they have. These are classified as serotypes. There are common serotypes that cause severe disease and are preventable by vaccination of children. Other less common types are more difficult to prevent. The investigators aim to determine the serotypes that cause invasive pneumococcal disease in Lebanon and to study their sensitivity to different antibiotics. The investigators will collect bacterial isolates from different hospitals in Lebanon isolated from the blood or spinal fluid of patients with invasive pneumococcal disease. This information will help the investigators determine the usefulness of available pneumococcal vaccines in preventing these infections. The data will be distributed to all primary care physicians treating children in Lebanon and will be shared with the Ministry of Health.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 700
• Est. completion date: October 2030
• Est. primary completion date: October 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Day and older

Eligibility

Inclusion Criteria:

• Samples included in the study are those that are:
• culture proven
• invasive pneumococcal infections
• in patients of all ages admitted to different hospitals all over Lebanon
• Acceptable samples include:
• positive isolates from blood
• cerebrospinal fluid
• other normally sterile body sites such as empyema fluid, abscesses, joint fluid, middle ear fluid obtained by tympanocentesis in the operating room, and lung needle aspiration

Exclusion Criteria:

• non S. pneumoniae isolates

Related Conditions & MeSH terms

• Bacteremia
• Meningitis
• Pneumonia
• Sepsis

Locations

Country	Name	City	State
Lebanon	American University of Beirut	Beirut

Sponsors (3)

Lead Sponsor	Collaborator
American University of Beirut Medical Center	Pfizer, PneumoADIP

Country where clinical trial is conducted

Lebanon, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serotype prevalence of S. pneumoniae in invasive pneumococcal disease		yearly
Secondary	Determine the antibiotic sensitivity of S. pneumoniae and the association with specific serotypes		yearly